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Objective. To determine the relationship between serum vitamin A and E and apolipoprotein levels in type 2 
diabetic patients. 
Setting. Shariati Hospital, Tehran, Iran. 
Subjects and methods. One hundred and seventeen eligible type 2 diabetic patients who attended the 
Endocrine Research and Metabolism Center between 2002 and 2004 were enrolled in the study. Blood samples 
were collected after a 12 - 14-hour overnight fast for the measurement of serum levels of total cholesterol, 
triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein (apo) A1 and apoB, 
and vitamins A and E. Anthropometric indices were determined by physical examination. Data were analysed 
statistically using Pearson’s coefficient, multiple regression, and partial and bivariate correlations. 
Results. The mean body mass index (BMI) of the subjects was 27.4 ± 3.7 kg/m2. The mean (± standard deviation 
(SD)) serum levels of vitamins A and E were 0.5 ± 0.1 μg/ml and 9.5 ± 2.6 μg/ml, respectively. There were no 
significant differences in the plasma levels of vitamins A and E in males and females. Mean serum levels of 
vitamins A and E were within the normal range for both sexes. Serum lipid levels (total cholesterol, triglyceride 
and apoB) correlated with serum levels of vitamin E (p < 0.05). Serum levels of vitamins A and E were also 
correlated (p < 0.05). Standardised vitamin E levels showed significant negative correlation with most studied 
lipid profiles (p < 0.05). 
Conclusion. This study found that mean serum levels of the natural antioxidants vitamin E, and especially 
vitamin A, were close to the lower end of the normal range of these antioxidants in type 2 diabetics. Also, serum 
vitamin E and standardised vitamin E levels were important predictors of serum apoA1 levels in these patients.
ARTICLE
Association between vitamin A and E and 
apolipoprotein A and B levels in type 2 
diabetes
Increased free radical activity has been reported in 
patients with type 2 diabetes mellitus (DM).1 Tissue 
damage by free radicals (oxidative stress) is thought 
to be an important factor in the pathogenesis of DM 
and its complications.2 Diabetic patients have been 
shown to have a high frequency of atherosclerosis, 
leading to increased risk of stroke and/or myocardial 
infarction.3 Individuals with DM are 2 - 4 times more 
likely to die of heart disease than those without DM, 
and cardiovascular disease (CVD) is responsible for 80% 
of diabetes-related deaths.4 
Lipoprotein abnormalities have been identified among 


























increase in CVD in DM patients.5 Recently, it has been 
found that reduced levels of apolipoprotein (apo) A1 
are associated with an increase in coronary events.6 
In addition, apoA1 has been reported to be a better 
predictor of cardiovascular events than low-density 
lipoprotein (LDL)7,8 and the strongest independent 
risk factor among high-density lipoprotein (HDL) 
parameters.9,10 
Vitamin E functions in vivo as a chain-breaking 
antioxidant and prevents propagation of free radical 
damage in biological membranes.11 Cell membrane 
damage is most effectively prevented by vitamin E, 
which reacts with peroxyl and hydroxyl radicals.12 It 
has been found that administration of pharmacological 
doses of vitamin E is a useful tool to reduce oxidative 
stress and to improve insulin action in healthy and 
in type 2 DM patients.13 Serum lipid levels have been 
correlated positively with vitamins A and E.14 Thus, 
vitamins A and E, which have antioxidant properties, 
may moderate the effects of oxidative stress.
Several studies measuring serum concentrations 
of vitamins A and E in type 1 and 2 DM patients 
have shown different results, possibly owing to 
differences in patient selection or the effects of dietary 
management.15-17 The objective of the present study 
was to investigate the relationship between serum 
levels of vitamin A and E and apoA1 and apoB in type 2 
DM patients.
The study was hospital-based. One-hundred and 
seventeen volunteer type 2 DM patients, 61 men and 
56 women, aged 29 - 73 years, who attended the 
Endocrine Research and Metabolism Center at Shariati 
Hospital, Tehran, Iran, between the years 2002 and 
2004 and who met the inclusion criteria, were enrolled 
in the study. The sample size was chosen based on 
the level of vitamin A, with 80% of statistical power to 
detect 20% differences at 5% significance level. 
A patient had to meet the following criteria to be 
included in the study: willingness to co-operate with 
the study, normal hepatic and renal function, no history 
of myocardial infarction or other diabetic complications, 
not on vitamin supplements, thyroid hormones, 
oestrogens, progesterons, diuretics or b-blockers, and in 
the case of female patients, not pregnant. The subjects 
were fully informed of the purposes, procedures and 
hazards of the study. Written informed consent was 
obtained from all participants. The research protocol 
was approved by the Ethics Committee on Human 
Experimentation of Tehran University of Medical 
Sciences, Iran.
Data on medical history, type of medication, dietary 
supplementation and smoking habits were obtained 
from face-to-face interviews using a pre-tested 
standardised questionnaire. Height was measured 
with patients standing barefoot against a wall-fixed 
tape. Weight was measured with subjects wearing 
light clothing and standing barefoot on a platform 
scale, with a 1.0 kg subtraction to correct for the 
weight of clothing. Waist circumference was measured 
between the lower rib margin and the iliac crest. 
Hip circumference was measured at the largest 
circumference.18 The body mass index (BMI) was 
calculated as weight/height2 (kg/m2) and the waist-
to-hip ratio (WHR) as the ratio between the waist and 
hip circumferences. The WHR cutoffs for defining 
abdominal obesity are more than 0.95 and 0.80 for men 
and women, respectively.19 
Subjects fasted overnight for 12 - 14 hours. Thereafter, 
at between 08h00 and 10h00, and before taking any 
oral hypoglycaemic agent(s), 20 ml blood samples 
were collected from each subject in tubes free from 
trace elements. Blood samples were centrifuged 
at 3 000 revolutions per minute for 10 minutes and 
aliquots of serum were transferred to polystyrene 
tubes which were immediately stored at –70°C until 
analysis. During the analysis, samples were protected 
from light and haemolysed samples were discarded. 
Serum alpha (α)-tocopherol (α-TOH) and vitamin 
A levels were determined using high-performance 
liquid chromatography according to the methodology 
described by Sanz and Santa-Cruz.20 Lipid-standardised 
α-TOH (LS-α-TOH) was calculated as serum α-TOH 
concentration expressed per milligram triglycerides 
(TGs) plus cholesterol (μg/mg). Serum TGs and total 
cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C) and low-density lipoprotein cholesterol (LDL-
C) were measured enzymatically, and apoA1 and 
apoB were measured using the immunoturbidimetric 
method.21 The intra- and inter-assay coefficient of 
variation was < 5%. The guidelines set by Fischenbach 
and Dunning22 were used to determine the lipid profile. 
According to the standards established for vitamin A 
and E status,23-25 serum retinol levels > 20 μg/ml and  
α-TOH > 5 μg/ml were considered normal. Intra- and 
inter-assay coefficient variation were 4.5% and 5% for 
retinol and 2% and 6% for α-TOH, respectively.
Descriptive and comparative statistics were performed 
for each variable. Analyses, such as the Pearson’s 
correlation test, the Student’s t-test, and multiple 
regression, were done. Log transformation was used 
to normalise the distribution of TG (log-TG). All other 
variables were normally distributed. A value of p < 0.05 
was considered to be statistically significant. All data 
were analysed using SPSS version 11.5.
Table I shows the mean (± standard deviation (SD)) 
age, duration of diabetes, BMI, WHR and smoking 
status of the study subjects. Fifty-two per cent of the 
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subjects were male, and the mean age of females was 
significantly lower than that of males (p < 0.0001). 
The mean age of both sexes was 53.3 ± 10.7 years. 
The patients had been diabetic for between 1 and 32 
years, with a mean duration of 8.9 ± 7.0 years.  Based 
on BMI, 36% of male and 48% of female patients were 
overweight (BMI 26 - 30 kg/m²) and 21% of male and 
25% of female patients were obese (BMI > 30 kg/m²). 
Based on WHR, 36% of male and 50% of female patients 
had abdominal obesity. Mean WHR was higher for 
men than for women (p < 0.0001). Eighty-five per cent 
of the patients were non-smokers and the proportion 
of smokers was higher among men than women (p = 
0.05). There were no significant differences in the mean 
serum levels of vitamins A and E between smokers and 
non-smokers (p > 0.5).
Table II shows the serum levels of vitamins E and A, 
lipids and lipoproteins. With the exception of TGs, all 
the other variables had normal distributions. Six out of 
61 patients (9.8%) had serum vitamin E levels < 5 μg/ml 
and 8 patients (13%) were below the desirable range for 
serum vitamin A levels. 
The serum TG values for 25 males (41%) and 28 females 
(50%), and TC values for 27 males (44%) and 18 females 
(32%) were within the desirable range. The mean serum 
levels of cholesterol and LDL-C were higher than the 
desirable range. Thirty-one per cent of male and 45% 
of female patients had serum apoA1 levels higher than 
normal values. The mean serum levels of apoB in both 
sexes were higher than the desirable range, with 82% of 
male and 62.5% of female patients having serum apoB 
Variables Male (N = 61) Female (N = 56) p-value
Ages (yrs) 57.1 ± 10.4 (29 - 71) 49.1 ± 9.6 (32 - 73) 0.0001*
Duration of diabetes (yrs) 10.0 ± 8.0 (1 - 32) 7.8 ± 5.5 (1 - 20) 0.250
BMI (kg/m2) 27.1 ± 3.5 (19.3 - 35.5) 27.7 ± 3.8 (19.0 - 37.5) 0.446
Waist/hip ratio 0.95 ± 0.1 (0.82 - 1.68) 0.84 ± 0.1 (0.65 - 0.98) 0.0001*




Table I.     Age, duration of diabetes, BMI, waist/hip ratio and smoking status of the study subjects 
(mean ± standard deviation) (range)
Variables Male (N = 61) Female (N = 56) Desirable range29
Vitamin E (μg/ml) 9.6 ± 2.8   9.5 ± 2.2 5 - 18
 (2.5 - 14.2) (5.3 - 14.8)  
Vitamin A (μg/ml) 0.5 ± 0.1 0.4 ± 0.1 0.36 - 1.2
 (0.2 - 0.6) (0.3 - 0.6)  
Standardised vitamin E* (μg/dl) 2.6 ± 0.8 2.6 ± 0.9 ND
 (0.8 - 4.5) (1.1 - 5.0) 
Total cholesterol (mg/dl) 210 ± 41    227 ± 52 < 200
 (134 - 307) (110 - 369)  
LDL-C (mg/dl) 139.6 ± 28.6 140.8 ± 35.3 < 130
 (92 - 217) (56 - 211) 
HDL-C (mg/dl) 48.3 ± 8.6  55.8 ± 9.2 Male: 35 - 65
 (31 - 68)† (31 - 75) Female: 35 - 80
Triglyceride (mg/dl) 171.0 ± 80 171.8 ± 23 < 150
 (60 - 570) (53 - 566) 
apoA1 (mg/dl) 145.3 ± 19.1 167.6 ± 23.3 Male: 90 - 155
 (20 - 197) (70 - 218) Female: 94 - 172 
apoB (mg/dl) 127.6 ± 25.9 123.6 ± 31.9 Male: 55 - 100
 (80 - 202) (45 - 188) Female: 45 - 110
TC/HDL-C ratio 4.4 ± 1.0 4.2 ± 1.1 3 - 6
 (2.8 - 8.2) (1.9 - 6.5) 
LDL-C/HDL-C ratio 2.9 ± 0.6 2.6 ± 0.7 Low risk: M: 1.00
 (1.9 - 4.5)‡ (0.9 - 4.2)                 F: 1.47
   Moderate risk: M: 3.55
                           F: 3.22
*Standardised vitamin E is calculated as μg serum α-tocopherol concentration expressed as per mg (cholesterol + triglyceride).  
†
Statistical significance p < 0.0001.
‡
Statistical significance p < 0.05.
ND = not determined; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; TC = total cholesterol; apo = apolipoprotein. 
Table II.    Serum levels of vitamin A and E, lipids and lipoproteins for the study subjects (mean ± 
standard deviation) (range)

















levels higher than the normal range. The mean ratio 
of TC/HDL-C was within the normal range. The mean 
ratio of LDL/HDL was higher than the desirable range. 
Therefore, 18% of male and 14% of female patients were 
at moderate risk of developing CVD. The serum HDL-C 
levels of 4 males (6.6%) and 1 female (1.8%) were below 
the desirable range. Women had significantly higher 
serum HDL-C levels (p < 0.0001) and lower LDL-C/HDL-
C ratios (p < 0.05) than men.  
Vitamin E levels were positively correlated with lipid 
profiles (Fig. 1). Significant correlations were observed 
between serum vitamin E levels and serum levels of 
vitamin A, cholesterol, log-TG, and apoB (r = 0.22,  
p < 0.05; r = 0.23, p < 0.05; r = 0.26, p = 0.004; r = 0.21, 
p < 0.05, respectively). 
Standardised serum vitamin E levels showed significant 
negative correlations with the serum levels of log-TG, 
cholesterol, apoB, LDL and the ratio of LDL/HDL and 
TCH/HDL (r = –0.53, p < 0.0001; r = –0.45, p < 0.0001;  
r = –0.40, p < 0.0001; r = –0.30, p < 0.0001; r = –0.38,  
p < 0.0001; r = –0.50, p < 0.0001, respectively (Fig. 2). 
Multiple regression analysis showed significant 
correlations between serum apoA1 levels and the levels 
of log-TG (p = 0.05), cholesterol (p < 0.05), vitamin E (p 
< 0.05), standardised vitamin E (p < 0.05) and HDL (p < 
0.0001). Similar analysis for the serum apoB levels and 
the levels of other variables showed only significant 
correlation with the LDL levels (p < 0.0001). 
The limitations of this study were not collecting dietary 
intake data or having a control group for comparison. 
Probable sources of error were duration of the study 
for collecting data.  Based on BMI, 27 patients (23%) 
were obese. Obese adults are considered to be at risk 
for developing chronic diseases.26 A 20% increase in 
body weight substantially increases the risk of lipid 
disorders and type 2 DM.26 A strong association exists 
between obesity and DM.27 In fact, obesity can be 
considered the most ‘environmental’ determinant in the 
development of diabetes.28 Obesity is associated with 
hyperinsulinaemia and insulin resistance in diabetes.29 
Waist circumference and WHR are similarly correlated 
with the risk of coronary heart disease (CHD).30 In our 
study group, 43% of patients had abdominal obesity 
and were at risk of developing CHD.
The relationship between obesity and insulin resistance 
is well established, but the molecular mechanisms 
involved are poorly understood.31 Moreover, obesity is 
associated with accelerated oxidative stress32-33 which 
aggravates vascular changes and induces early CVD.34 
It has been demonstrated that oxidative stress is higher 
in obese diabetic than in obese non-diabetic subjects.35-
36 
Impaired glucose tolerance is often associated with 
obesity and raised levels of plasma free fatty acids.37 
Previous investigators have demonstrated that 
patients with type 2 DM have higher serum vitamin 
A concentrations than normal subjects.15-17 Tavridou 
et al.2 also found serum vitamin A levels to be higher 
in subjects with impaired glucose tolerance (IGT). 
Their data suggest that higher serum vitamin A 
concentrations exist in subjects before the onset of 
diabetes. Sasaki et al.17 have shown that the increased 
vitamin A levels in type 2 DM occur independently of 
lipid status. In their study, vitamin A levels showed a 
positive correlation with apoC-II in both diabetic and 
control subjects. Furthermore, Tavridou et al.2 found 
positive correlations between the serum vitamin A 
levels and both serum triglyceride and cholesterol levels 
in IGT patients. The average serum vitamin A and E 
levels were within the desirable range in our study 
(Table II).
Discussion 
Fig. 1. Correlation between levels of vitamin E and 
vitamin A, cholesterol, log-triglyceride and apoB in the 
study group.
Fig. 2. Correlation between levels of standardised 
vitamin E and cholesterol, log-triglyceride, TCH/HDL 



































































































































Gouado et al.14 also found a strong correlation between 
vitamins A and E in healthy people. In the present 
study the serum vitamin A levels did not show any 
significant correlation with the investigated serum 
variables, except for vitamin E, and this relationship 
remained significant after adjusting for serum log-TG 
concentrations. The significant links observed between 
vitamin A and E may suggest similar pathways of 
absorption and blood transportation of these vitamins, 
with lipoproteins or other specific binding proteins.38 
In our study, the serum vitamin E levels showed 
significant correlation with serum cholesterol, log-TG 
and apoB levels (Fig. 1), which is similar to the results 
of Gouado et al.,14 whereas the standardised vitamin 
E levels showed significant negative correlations 
with most of the serum levels of lipid profiles (Fig. 
2). Furthermore, multiple regression analysis showed 
significant correlations between serum levels of apoA1 
and vitamin E, standardised vitamin E and HDL. These 
findings may suggest that serum levels of vitamin E, 
standardised vitamin E and HDL could be considered 
predictors of apoA1 status. 
Farvid et al.39 found that co-supplementation with 
vitamin E, vitamin C, magnesium and zinc increased 
serum levels of HDL-C and apoA1 after 3 months of 
intervention in type 2 DM patients. In their study, 
positive correlation existed between changes in serum 
vitamin E, HDL-C and apoA1. HDL may protect against 
CHD through reverse cholesterol transport and also 
antioxidant and anti-inflammatory properties.6 Because 
of its antioxidative role, vitamin E may protect HDL-
C and apoA1 from oxidation, and increase the rate of 
reverse cholesterol transport.
Serum levels of apoB and apoA1 and the ratio of apoB/
apoA1 have been reported to be better predictors of 
cardiovascular events than LDL-C alone.8 They have 
even been shown to retain their predictive power 
in patients receiving lipid-modifying therapy.8 In 
addition, apoA1 levels have been reported as the 
strongest independent risk factor indicator among 
HDL parameters.9,10 Low levels of HDL-C increase 
cardiovascular risk and are associated with insulin 
resistance, hypertension, DM, high levels of TG 
and LDL-C, and a precoagulant state.39 As potent 
antioxidants, serum carotenoids may also play a pro-
tective role in the development of chronic diseases 
including CVD.40-42 Beta-carotene could decrease the 
oxidative susceptibility of LDL.43 Serum carotenoid 
levels are inversely associated with type 2 DM and 
impaired glucose metabolism.44 As a major water-
soluble antioxidant, vitamin C acts as the first line of 
defence during oxidative stress. Its blood concentration 
is solely dependent on dietary intake, but once it is 
oxidised it can be reduced back to its antioxidant form 
by glutathione.45 Vitamin C can regenerate vitamin E 
through redox cycling, thus it plays an important role in 
protein thiol group protection against oxidation.46 
Supplementation with vitamin E or a combination 
of vitamin E and other nutrients or non-nutrients 
could increase serum HDL-C and apoA1 levels.31,47,48 
Meksawan et al.49 found that subjects on a low-fat diet 
(19%) had significantly lower serum HDL-C and apoA1 
levels than those on a high-fat diet (50%). Therefore, 
it seems that manipulating levels of vitamin E intake, 
with or without other nutrient manipulation, could 
impact favourably on apolipoprotein profile, especially 
apoA1, in terms of decreasing CVD risk. 
Vitamin E is the major lipid-soluble antioxidant in cell 
membranes and plasma lipoproteins.37 It reacts with 
the lipid peroxide radicals formed by peroxidation of 
polyunsaturated fatty acids before they can establish a 
chain reaction. The tocopheroxyl free radical product 
is relatively non-reactive and can be reduced back to 
tocopherol by reaction with vitamin C from plasma. 
Tocopheroxyl could penetrate further into cells and 
potentially propagate a chain reaction.37 Although 
studies have shown an association between high blood 
concentrations of vitamin E and a lower incidence 
of atherosclerosis, this may explain why the effect 
of high doses of vitamin E has been disappointing. 
Standardised vitamin E may show a better relationship 
with lipid profile than vitamin E. 
In conclusion, mean serum levels of vitamin E, and 
especially vitamin A, were close to the lower end of the 
desirable range in our study group, but mean serum 
apoB levels were higher than the desirable range. 
Serum levels of vitamin E and standardised vitamin E 
may be considered predictors of serum apoA1 levels. 
These findings need confirmation by means of further 
research. More studies are required to demonstrate 
the benefits of vitamin A and E supplementation in 
improving the anti-oxidant status of diabetics by 
increasing serum levels of apoA1 and HDL in order to 
decrease the risk of CVD in these patients.
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remains to be seen how swiftly South Africa can obtain sup-
plies. 
Time Thami turns things around?
Health Department Director General Thami Mseleku has 
been appointed as the Registrar of Medicines at the 
Medicines Control Council as a stop-gap measure to avoid 
‘any further delays’ in the registration of medicines.
No cla ity coul  be obtained as to who will eventually take 
up the job full time.
Medicine registration backlogs are being described by 
industry sources as  ‘huge’, with delays of up to 40 months, 
twice the international average of 20 - 22 months.
AIDS drug almost impossible to obtain
Pressure is mounting on the Medicines Control Council 
to fast-track the registration of a safer antiretroviral drug. 
Called tenofovir, it is a replacement for the widely used 
d4T, which is proving to be highly toxic for many patients. 
Tenofovir is an important drug for patients who suffer from 
lactic acidosis, a life-threatening side-effect of the first-line 
antiretroviral d4T.
State condones ‘AIDS herbs’
The Health Department said that people who prefer to use 
traditional treatments for HIV/AIDS, even untested ones, 
must be allowed to do so. This follows a City Press report 
about H alth Minister Manto Tshabalala-Msimang’s advoca-
cy of herbal medicine. ‘People who prefer to use traditional 
medicines should be allowed to use them,’ said the depart-
ment spokesperson, Sibani Mngadi. Asked whether the use 
of untested treatments was not a concern, he said ‘The issue 
with t aditional medicines is that they become available on 
whatever knowledge the practitioner has. What the depart-
ment emp asises is that we need to invest more in research 
and development of traditional medicines.’ The DA said 
Tshabalala-Msimang would be responsible for any deaths 
resulting from her alleged promotion of ntested treatments.
Traditional AIDS drug distributed
The Health Minister gave her support to yet another untested 
AIDS drug and the health department said that those who 
try to prevent the distribution of th  drug – a ‘tr itional 
African medicine’ called Ubhejane – were racists who 
wanted to undermine African medicin s. Ubhejane is being 
distributed among people with HIV and AIDS in KwaZulu-
Natal and has not been clinically tested. 
SA to e se en ry for foreign specialists
In the first major dev lopment since Presi ent Thabo Mbeki’s 
state-of-the nation undertaking to attract scarce skills to the 
country, government has publi hed  compre e sive list of 
skilled professionals who can apply for permits. Immigration 
Act regulations have long been criticised for making it dif-
ficult fo  local and foreign companies to import skills. It’s 
the first time government has specified the professional 
categories that work permit qu tas will apply to since the 
new Immigration Act was adopted. These regulations are a 
major departure from the system that required proof that a 
South African could not have filled the post.
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